Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 5/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11703082 | 0.89 | ALDH1A1 (0.40) | ALDH1A1THRBL3MBTL1DRD3NAAA | |
| SCHEMBL1708734 | 0.83 | — | — | |
| SCHEMBL725118 | 0.82 | POLB (0.40) | ALDH1A1THRBL3MBTL1DRD3PKM | |
| SCHEMBL24864597 | 0.80 | DAO (0.32) | — | |
| SCHEMBL3042153 | 0.80 | KDM4E (0.45) | ALDH1A1KDM4ELMNAMAPTSMN1; SMN2 | |
| SCHEMBL16271560 | 0.79 | CARM1 (0.44) | SMN1; SMN2 | |
| SCHEMBL16271565 | 0.79 | ALDH1A1 (0.41) | ALDH1A1KDM4ELMNACYP1A2KMT2A | |
| SCHEMBL17722879 | 0.79 | — | — | |
| SCHEMBL18027710 | 0.75 | PIK3CD (0.33) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7576106 | 0.75 | PIK3CD (0.33) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | PFIZER, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | PFIZER, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | PFIZER, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| EP-1753763-B1 | INDAZOLE AND INDOLONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | PFIZER LTD (GB) | 2008-08-13 | — | — | EP | disclosed |
| EP-1753763-B1 | INDAZOLE AND INDOLONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | PFIZER LTD (GB) | 2008-08-13 | — | — | EP | disclosed |
| EP-1758862-A1 | AMINOPYRIDINE DERIVATIVES AS SELECTIVE DOPAMINE D3 AGONISTS | Pfizer Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| EP-1753763-A2 | INDAZOLE AND INDOLONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | Pfizer Limited (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20050288270-A1 | New aminopyridine derivatives and their use as pharmaceuticals | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| WO-2005115985-A1 | AMINOPYRIDINE DERIVATIVES AS SELECTIVE DOPAMINE D3 AGONISTS | PFIZER LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005116027-A2 | INDAZOLE AND INDOLONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | PFIZER LIMTED (GB) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267096-A1 | New indazole and indolone derivatives and their use pharmaceuticals | PFIZER INC | 2005-12-01 | — | — | US | disclosed |
| US-5206157-A | Cyclization of n-substituted dialkanolamine using Gluconobacter | TEXACO INC. (US) | 1993-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288270-A1 | New aminopyridine derivatives and their use as pharmaceuticals | DRD2, DRD1, DRD3 | ALDH1A1 792/4885THRB 2692/4885L3MBTL1 4477/4885 |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | DRD2, DRD1, DRD3 | ALDH1A1 1067/4885THRB 2280/4885L3MBTL1 4182/4885 |
| US-20050267096-A1 | New indazole and indolone derivatives and their use pharmaceuticals | DRD2, DRD3, DRD1 | ALDH1A1 708/4885THRB 2285/4885L3MBTL1 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.